Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (201-210 of 232) with videos related to

Pageof 24
Sort By:
Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.
Cancer|August 15, 1980
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's diseaseM R Cooper, T F Pajak, N I Nissen, et al.
Blood|August 24, 2011
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsAngela G Fleischman, Karl J Aichberger, Samuel B Luty, et al.
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
Leukemia|March 9, 2018
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetTiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Pageof 24

Showing results (201-210 of 232) with videos related to

Sort By:
Pageof 24
Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.
Cancer|August 15, 1980
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's diseaseM R Cooper, T F Pajak, N I Nissen, et al.
Blood|August 24, 2011
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasmsAngela G Fleischman, Karl J Aichberger, Samuel B Luty, et al.
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
Leukemia|March 9, 2018
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetTiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Pageof 24